v3.25.4
Contract revenues - Anti-Abeta Active Immunotherapy in AD - 2024 agreement Takeda Pharmaceuticals, USA Inc. (Details)
SFr in Thousands, $ in Millions
1 Months Ended 12 Months Ended
May 31, 2024
CHF (SFr)
May 31, 2024
USD ($)
Dec. 31, 2025
CHF (SFr)
Dec. 31, 2024
CHF (SFr)
Dec. 31, 2023
CHF (SFr)
May 31, 2024
USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Contract revenue     SFr 3,573 SFr 27,309 SFr 14,801  
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc.            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Collaborative agreement, upfront payments received SFr 92,300 $ 100.0        
Period to provide notice of termination of agreement 90 days 90 days        
Transaction price SFr 92,300         $ 100.0
Number of development milestones that may occur prior to option exercise included in transaction price 0         0
Contract revenue     3,573 2,709 SFr 0  
Deferred revenue     SFr 86,000 SFr 89,600    
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option and development, CMC and regulatory activities            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Transaction price SFr 92,300         $ 100.0
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Transaction price SFr 80,700         87.4
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Development, CMC and regulatory activities            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Number of performance obligations identified 1 1        
Transaction price SFr 11,600         12.6
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Maximum            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Collaborative agreement, potential receivables for option exercise fee and potential development, commercial and sales-based milestones SFr 1,700         $ 2.1